Oral contraceptives and breast cancer risk overall and by molecular subtype among young women

Cancer Epidemiology Biomarkers and Prevention

Volumn 23, Issue 5, 2014, Pages 755-764

  Beaber, Elisabeth F ^a,b   Malone, Kathleen E ^a,b   Tang, Mei Tzu Chen ^a   Barlow, William E ^a,b   Porter, Peggy L ^a,b   Daling, Janet R ^a,b   Li, Christopher I ^a,b  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESOGESTREL; DROSPIRENONE; ESTROGEN RECEPTOR; LEVONORGESTREL; NORETHISTERONE; NORETHISTERONE ACETATE; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT;

ADULT; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER RISK; CONTRACEPTIVE BEHAVIOR; CONTROLLED STUDY; DRUG USE; ESTROGEN RECEPTOR NEGATIVE BREAST CANCER; FEMALE; HUMAN; INTERVIEW; LIFESPAN; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; TREATMENT DURATION; TRIPLE NEGATIVE BREAST CANCER; TUMOR INVASION; AGE; BREAST NEOPLASMS; CASE CONTROL STUDY; CHEMICALLY INDUCED; CLASSIFICATION; COMPARATIVE STUDY; FOLLOW UP; METABOLISM; PROGNOSIS; RISK; RISK FACTOR; TRIPLE NEGATIVE BREAST NEOPLASMS; UNITED STATES; YOUNG ADULT;

ADULT; AGE FACTORS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CONTRACEPTIVES, ORAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; ODDS RATIO; PROGNOSIS; RECEPTORS, ESTROGEN; RISK FACTORS; TRIPLE NEGATIVE BREAST NEOPLASMS; UNITED STATES; YOUNG ADULT;

EID: 84899759009     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-13-0944     Document Type: Article

References (50)

1. Gerstman BB, Burke L, Delaney J, McLellan B. Steroidal contraceptive use update, United States, 1989-1994. Pharmacoepidemiol Drug Saf 1996;5: 141-7.
2. Gerstman BB, Gross TP, Kennedy DL, Bennett RC, Tomita DK, Stadel BV. Trends in the content and use of oral contraceptives in the United States, 1964-88. Am J Public Health 1991;81: 90-6.
3. O'Brien SH, Kaizar EE, Gold MA, Kelleher KJ. Trends in prescribing patterns of hormonal contraceptives for adolescents. Contraception 2008;77: 264-9.
4. Wallach M, Grimes D, editors. Modern oral contraception: updates from the contraception report. Totowa, NJ: Emron; 2000.
5. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347: 1713-27.
6. Hunter DJ, Colditz GA, Hankinson SE, Malspeis S, Spiegelman D, Chen W, et al. Oral contraceptive use and breast cancer: a prospective study of young women. Cancer Epidemiol Biomarkers Prev 2010;19: 2496-502.
7. Marchbanks PA, McDonald JA, Wilson HG, Folger SG, Mandel MG, Daling JR, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med 2002;346: 2025-32.
8. Rosenberg L, Zhang Y, Coogan PF, Strom BL, Palmer JR. A casecontrol study of oral contraceptive use and incident breast cancer. Am J Epidemiol 2009;169: 473-9.
9. Ursin G, Ross RK, Sullivan-Halley J, Hanisch R, Henderson B, Bernstein L. Use of oral contraceptives and risk of breast cancer in young women. Breast Cancer Res Treat 1998;50: 175-84.
10. Brinton LA, Daling JR, Liff JM, Schoenberg JB, Malone KE, Stanford JL, et al. Oral contraceptives and breast cancer risk among younger women. J Natl Cancer Inst 1995;87: 827-35.
11. Moorman PG, Millikan RC, Newman B. Oral contraceptives and breast cancer among African-American women and White women. J Natl Med Assoc 2001;93: 329-34.
12. Rosenberg L, Palmer JR, Rao RS, Zauber AG, Strom BL, Warshauer ME, et al. Case-control study of oral contraceptive use and risk of breast cancer. Am J Epidemiol 1996;143: 25-37.
13. Shapiro S, Rosenberg L, Hoffman M, Truter H, Cooper D, Rao S, et al. Risk of breast cancer in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen contraceptives. Am J Epidemiol 2000;151: 396-403.
14. White E, Malone KE, Weiss NS, Daling JR. Breast cancer among young U.S. women in relation to oral contraceptive use. J Natl Cancer Inst 1994;86: 505-14.
15. Wingo PA, Lee NC, Ory HW, Beral V, Peterson HB, Rhodes P. Agespecific differences in the relationship between oral contraceptive use and breast cancer. Obstet Gynecol 1991;78: 161-70.
16. Dolle JM, Daling JR,White E, Brinton LA, DoodyDR, Porter PL, et al. Risk factors for triple-negative breast cancer in women under the age of 45 years. Cancer Epidemiol Biomarkers Prev 2009;18: 1157-66.
17. Mosher WD, Jones J. Use of contraception in the United States: 1982-2008. Vital Health Stat 23 2010;29: 1-44.
18. Li CI, Beaber EF, Tang MT, Porter PL, Daling JR, Malone KE. Effect of depo-medroxyprogesterone acetate on breast cancer risk among women 20 to 44 years of age. Cancer Res 2012;72: 2028-35.
19. Waksberg J. Sampling methods for random digit dialing. J Am Stat Assoc 1978;73: 40-6.
20. Hall KS, Trussell J, Schwarz EB. Progestin-only contraceptive pill use among women in the United States. Contraception 2012;86: 653-8.
21. Liang SY, Grossman D, Phillips KA. User characteristics and out-ofpocket expenditures for progestin-only versus combined oral contraceptives. Contraception 2012;86: 666-72.
22. Benagiano G, Primiero FM, Farris M. Clinical profile of contraceptive progestins. Eur J Contracept Reprod Health Care 2004;9: 182-93.
23. Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, et al. Classification and pharmacology of progestins. Maturitas 2003;46:S7-S16.
24. Stanczyk FZ. Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception. Rev Endocr Metab Disord 2002;3: 211-24.
25. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: further results. Contraception 1996;54: 1S-106S.
26. Hankinson SE, Colditz GA, Manson JE, Willett WC, Hunter DJ, Stampfer MJ, et al. A prospective study of oral contraceptive use and risk of breast cancer (Nurses' Health Study, United States). Cancer Causes Control 1997;8: 65-72.
27. Kumle M, Weiderpass E, Braaten T, Persson I, Adami HO, Lund E. Use of oral contraceptives and breast cancer risk: The Norwegian-Swedish Women's Lifestyle and Health Cohort Study. Cancer Epidemiol Biomarkers Prev 2002;11: 1375-81.
28. Van Hoften C, Burger H, Peeters PH, Grobbee DE, Van Noord PA, Leufkens HG. Long-term oral contraceptive use increases breast cancer risk in women over 55 years of age: the DOM cohort. Int J Cancer 2000;87: 591-4.
29. Althuis MD, Brogan DR, Coates RJ, Daling JR, Gammon MD, Malone KE, et al. Hormonal content and potency of oral contraceptives and breast cancer risk among young women. Br J Cancer 2003;88: 50-7.
30. Dumeaux V, Alsaker E, Lund E. Breast cancer and specific types of oral contraceptives: a large Norwegian cohort study. Int J Cancer 2003;105: 844-50.
31. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. Oral-contraceptive use and the risk of breast cancer. N Engl J Med 1986;315: 405-11.
32. Marchbanks PA, Curtis KM, Mandel MG, Wilson HG, Jeng G, Folger SG, et al. Oral contraceptive formulation and risk of breast cancer. Contraception 2012;85: 342-50.
33. Ma H, Wang Y, Sullivan-Halley J, Weiss L, Marchbanks PA, Spirtas R, et al. Use of four biomarkers to evaluate the risk of breast cancer subtypes in the women's contraceptive and reproductive experiences study. Cancer Res 2010;70: 575-87.
34. Althuis MD, Brogan DD, Coates RJ, Daling JR, Gammon MD, Malone KE, et al. Breast cancers among very young premenopausal women (United States). Cancer Causes Control 2003;14: 151-60.
35. Cotterchio M, Kreiger N, Theis B, Sloan M, Bahl S. Hormonal factors and the risk of breast cancer according to estrogen- and progesteronereceptor subgroup. Cancer Epidemiol Biomarkers Prev 2003;12: 1053-60.
36. Huang WY, Newman B, Millikan RC, Schell MJ, Hulka BS, Moorman PG. Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status. Am J Epidemiol 2000;151: 703-14.
37. Ma H, Bernstein L, Ross RK, Ursin G. Hormone-related risk factors for breast cancer in women under age 50 years by estrogen and progesterone receptor status: results from a case-control and a case-case comparison. Breast Cancer Res 2006;8:R39.
38. Rosenberg L, Boggs DA, Wise LA, Adams-Campbell LL, Palmer JR. Oral contraceptive use and estrogen/progesterone receptor-negative breast cancer among African American women. Cancer Epidemiol Biomarkers Prev 2010;19: 2073-9.
39. Sweeney C, Giuliano AR, Baumgartner KB, Byers T, Herrick JS, Edwards SL, et al. Oral, injected and implanted contraceptives and breast cancer risk among U.S. Hispanic and non-Hispanic white women. Int J Cancer 2007;121: 2517-23.
40. BaoPP, Shu XO, Gao YT, Zheng Y, Cai H, Deming SL, et al. Association of hormone-related characteristics and breast cancer risk by estrogen receptor/progesterone receptor status in the shanghai breast cancer study. Am J Epidemiol 2011;174: 661-71.
41. Coulter A, Vessey M, McPherson K, Crossley B. The ability ofwomento recall their oral contraceptive histories. Contraception 1986;33: 127-37.
42. Hunter DJ, Manson JE, Colditz GA, Chasan-Taber L, Troy L, Stampfer MJ, et al. Reproducibility of oral contraceptive histories and validity of hormone composition reported in a cohort of US women. Contraception 1997;56: 373-8.
43. Nischan P, Ebeling K, Thomas DB, Hirsch U. Comparison of recalled and validated oral contraceptive histories. Am J Epidemiol 1993; 138: 697-703.
44. Norell SE, Boethius G, Persson I. Oral contraceptive use: interview data versus pharmacy records. Int J Epidemiol 1998;27: 1033-7.
45. West SL, Strom BL, Poole C. Validity of Pharmacoepidemiologic Drug and Diagnosis Data. In:Strom BL, editor. Pharmacoepidemiology. 4th ed. Chichester, England: John Wiley & Sons Ltd; 2005. p. 709-65.
46. Voigt LF, Schwartz SM, Doody DR, Lee SC, Li CI. Feasibility of including cellular telephone numbers in random digit dialing for epidemiologic case-control studies. Am J Epidemiol 2011;173: 118-26.
47. Franke HR, Jordaan AF, Wolbers F, Vermes I, Oostrom KA, van der Mooren MJ. Ex vivo measurement of cell apoptosis and proliferation in breast tissue of healthy women: influence of age and steroid status. An exploratory study. Eur J Obstet Gynecol Reprod Biol 2006;129: 96-8.
48. Isaksson E, von Schoultz E, Odlind V, Soderqvist G, Csemiczky G, Carlstrom K, et al. Effects of oral contraceptives on breast epithelial proliferation. Breast Cancer Res Treat 2001;65: 163-9.
49. Garcia y Narvaiza D, Navarrete MA, Falzoni R, Maier CM, Nazario AC. Effect of combined oral contraceptives on breast epithelial proliferation in young women. Breast J 2008;14: 450-5.
50. Williams G, Anderson E, Howell A, Watson R, Coyne J, Roberts SA, et al. Oral contraceptive (OCP) use increases proliferation and decreases oestrogen receptor content of epithelial cells in the normal human breast. Int J Cancer 1991;48: 206-10.